Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001780671 | SCV002022006 | likely pathogenic | not provided | 2021-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002541175 | SCV003254043 | uncertain significance | Ehlers-Danlos syndrome, spondylodysplastic type, 2; Spondyloepimetaphyseal dysplasia with joint laxity | 2023-10-17 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the B3GALT6 gene (p.Arg302Glnfs*142). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 28 amino acid(s) of the B3GALT6 protein and extend the protein by 113 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with B3GALT6-related conditions. ClinVar contains an entry for this variant (Variation ID: 1323966). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV005006047 | SCV005634658 | likely pathogenic | Al-Gazali syndrome; Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures; Ehlers-Danlos syndrome, spondylodysplastic type, 2 | 2024-05-09 | criteria provided, single submitter | clinical testing |